ExThera Medical

Executive Summary

ExThera Medical Corporation is a private medical device company focused on extracorporeal blood filtration to treat life-threatening bloodstream infections and metastatic cancer. Its lead product, the Seraph 100 Microbind Affinity Blood Filter, is designed to rapidly remove a broad spectrum of pathogens and inflammatory mediators from the blood, addressing critical unmet needs in sepsis and other infectious diseases. The company was founded in 2007 and has received regulatory approval (CE marking) in Europe, with ongoing efforts to expand commercial reach and clinical indications. ExThera is currently focused on expanding commercialization of Seraph 100, particularly in Europe and the Middle East, while pursuing U.S. FDA clearance. Key milestones include building real-world evidence through patient registries and seeking emergency use authorization or full approval in the U.S. The company also explores applications in oncology, such as removing circulating tumor cells. With a novel platform and growing clinical adoption, ExThera is well-positioned in the infectious disease and medical device markets, though it faces competition and regulatory hurdles.

Upcoming Catalysts (preview)

• Q2 2026FDA Emergency Use Authorization or Breakthrough Device Designation for Sepsis60% success
• Q3 2026Publication of Clinical Data from Ongoing U.S. Sepsis Trial70% success
• Q4 2026Commercial Expansion into New Geographies (e.g., Middle East, Asia)80% success